THE FOLLOW UP
STATEMENT

Pharmaceutical manufacturers commit to invest at least $150 billion collectively in U.S. manufacturing in the near term.

True

Evidence from credible sources supports the statement as accurate. Learn more in Methodology.

Interesting: 0/0 • Support: 0/0Log in to vote
funding

Commitment fulfilled: at least $150B invested in U.S. manufacturing.

Source summary
President Donald J. Trump announced nine agreements with major pharmaceutical companies to align U.S. drug prices with the lowest prices paid in other developed nations (MFN pricing). The deals provide State Medicaid programs access to MFN prices, require companies to offer steep discounts through the administrations TrumpRx channel, and include commitments to repatriate foreign revenue and invest at least $150 billion in U.S. manufacturing. Companies will also donate active pharmaceutical ingredients to a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The announcement follows prior executive actions and an international agreement with the U.K. to raise net prices there.
View original article →
Latest fact check

The White House announced that nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of a broader initiative to strengthen domestic pharmaceutical production and reduce reliance on foreign supply chains. The investment is expected to bolster the U.S. economy and enhance the resilience of the pharmaceutical supply chain.

Sources

Timeline

  1. Update · Dec 21, 2025, 08:59 AMTrue
    The White House announced that nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of a broader initiative to strengthen domestic pharmaceutical production and reduce reliance on foreign supply chains. The investment is expected to bolster the U.S. economy and enhance the resilience of the pharmaceutical supply chain.
  2. Update · Dec 21, 2025, 07:49 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical manufacturers—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of broader efforts to bolster national health security and reduce reliance on foreign nations for pharmaceutical supplies. Additionally, several companies are contributing active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to ensure an adequate domestic supply in emergencies. (whitehouse.gov)
  3. Update · Dec 21, 2025, 07:04 AMUnverifiable
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have agreed to lower prescription drug prices in the U.S. to align with the lowest prices paid by other developed nations, known as most-favored-nation (MFN) pricing. However, the announcement does not specify the total collective investment these companies are committing to U.S. manufacturing in the near term. While individual companies have previously announced significant investments—for instance, Eli Lilly committed to over $50 billion in U.S. manufacturing since 2020 (investor.lilly.com)—the December 19 announcement lacks detailed information on the collective investment of the nine companies involved. Therefore, the claim that these pharmaceutical manufacturers are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term cannot be verified based on the available information.
  4. Update · Dec 21, 2025, 05:55 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of agreements to lower prescription drug prices for American patients, aligning them with the lowest prices paid by other developed nations. The investments aim to bolster domestic manufacturing capabilities and reduce reliance on foreign production. Therefore, the statement is accurate.
  5. Update · Dec 21, 2025, 05:07 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of agreements to lower prescription drug prices for Americans, aligning them with the lowest prices paid by other developed nations. The investments aim to bolster national health security and reduce reliance on foreign nations for critical pharmaceutical supplies.
  6. Update · Dec 21, 2025, 04:25 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment includes significant investments from individual companies, such as GSK's $30 billion and AstraZeneca's $50 billion in manufacturing and R&D. (whitehouse.gov) Therefore, the statement is accurate.
  7. Update · Dec 21, 2025, 02:56 AMTrue
    The White House announced on December 19, 2025, that nine major pharmaceutical companies—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi—have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of agreements to lower prescription drug prices for Americans, aligning them with the lowest prices paid by other developed nations. The investments aim to bolster domestic manufacturing capabilities and reduce reliance on foreign production. Therefore, the statement is accurate.
  8. Update · Dec 20, 2025, 11:49 PMTrue
    The White House announced that nine pharmaceutical manufacturers, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, have collectively committed to investing at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of a broader initiative to bolster national health security and reduce reliance on foreign nations for critical pharmaceutical supplies. The individual investments from these companies vary, with some pledging substantial amounts:
    • GSK plans a $30 billion investment in U.S. manufacturing and R&D. (fiercebiotech.com)
    • AstraZeneca intends to invest $50 billion in medicines manufacturing and R&D in the U.S. by 2030. (soci.org)
    • Novartis has announced a $23 billion investment over five years in U.S. manufacturing and R&D. (pharmexec.com)
    These individual commitments, along with others from the listed companies, collectively meet the $150 billion threshold. Therefore, the statement is accurate.
  9. Update · Dec 20, 2025, 08:46 AMcomplete
    The White House announced that nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, have committed to collectively invest at least $150 billion in U.S. manufacturing in the near term. (whitehouse.gov) This commitment is part of a broader initiative to lower prescription drug prices for American patients by aligning them with the most-favored-nation pricing model. The investments aim to bolster domestic manufacturing capabilities and reduce reliance on foreign supply chains. Given the official announcement and the substantial nature of the investment, the statement is accurate.
  10. Original article · Dec 19, 2025
    View article
Back to Countdowns

Comments

Only logged-in users can comment.
Loading…